1. Mariette X, Criswell LA. Primary Sjögren’s syndrome. N Engl J Med 2018;378:931–939.

2. Lee KA, Nam BD, Hwang JH, Kim HS. Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren’s syndrome. Sci Rep 2023;13:9189.

3. Margaretten M. Neurologic manifestations of primary Sjögren syndrome. Rheum Dis Clin North Am 2017;43:519–529.

4. Tate A, Suárez-Calvet M, Ekelund M, et al. Precision medicine in neurodegeneration: the IHI-PROMINENT project. Front Neurol 2023;14:1175922.

5. Wang ZZ, Liu MS, Sun Z, et al. Risk of dementia or Par kinson’s disease in the presence of Sjögren’s syndrome: a systematic review and meta-analysis. Front Integr Neurosci 2022;16:1027044.

6. Varma VR, Desai RJ, Navakkode S, et al. Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease. Mol Psychiatry 2023;28:1312–1326.

7. Fardet L, Nazareth I, Petersen I. Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer’s disease: a population-based cohort study. Ann Rheum Dis 2019;78:279–282.

8. Lee KA, Kim J, Choi W, Kim HS, Seo GH. Pregnancy-associated risk factors and incidence of systemic sclerosis in primiparous women: a nationwide population-based cohort study. Mod Rheumatol 2022;32:149–154.

9. Ahn JK, Hwang J, Seo GH. Risk of non-Hodgkin’s lymphoma and thyroid cancer in primary Sjögren’s syndrome measured using the Korean Health Insurance Claims Database. Clin Exp Rheumatol 2020;38:Suppl 126. 40–46. 10. Cho SK, Kim H, Myung J, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a nationwide population-based study. J Korean Med Sci 2019;34:e55.

11. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–558.

12. Joh HK, Kwon H, Son KY, et al. Allergic diseases and risk of incident dementia and Alzheimer’s disease. Ann Neurol 2023;93:384–397.

13. Hou TY, Hsu HC, Lin TM, et al. Higher risk of dementia in primary Sjogren’s syndrome. Ann Clin Transl Neurol 2019;6:633–641.

14. Liliang PC, Liang CL, Lu K, et al. Population-based study suggests an increased risk of Alzheimer’s disease in Sjögren’s syndrome. Clin Rheumatol 2018;37:935–941.

15. Chen KT, Chen YC, Fan YH, et al. Rheumatic diseases are associated with a higher risk of dementia: a nation-wide, population-based, case-control study. Int J Rheum Dis 2018;21:373–380.

16. Chen HH, Perng WT, Chiou JY, Wang YH, Huang JY, Wei JC. Risk of dementia among patients with Sjogren’s syndrome: a nationwide population-based cohort study in Taiwan. Semin Arthritis Rheum 2019;48:895–899.

17. Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med 2015;3:136.

18. Wang YC, Lin MS, Huang AP, Wu CC, Kung WM. Association between systemic rheumatic diseases and dementia risk: a meta-analysis. Front Immunol 2022;13:1054246.

19. Yeung CHC, Au Yeung SL, Schooling CM. Association of autoimmune diseases with Alzheimer’s disease: a mendelian randomization study. J Psychiatr Res 2022;155:550–558.

20. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013;368:651–662.

21. Desai RJ, Varma VR, Gerhard T, et al. Targeting abnormal metabolism in Alzheimer’s disease: The Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study. Alzheimers Dement (N Y) 2020;6:e12095.

22. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455–460.

23. Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 2020;79:3–18.

24. Fauchais AL, Ouattara B, Gondran G, et al. Articular manifestations in primary Sjögren’s syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 2010;49:1164–1172.

25. Xu D, Zhao S, Li Q, et al. Characteristics of Chinese patients with primary Sjögren’s syndrome: preliminary report of a multi-centre registration study. Lupus 2020;29:45–51.

26. Wang X, Zhang T, Guo Z, et al. The efficiency of hydroxychloroquine for the treatment of primary Sjögren’s syndrome: a systematic review and meta-analysis. Front Pharmacol 2021;12:693796.

27. Custodio N, Montesinos R, Lira D, Herrera-Pérez E, Bardales Y, Valeriano-Lorenzo L. Mixed dementia: a review of the evidence. Dement Neuropsychol 2017;11:364–370.

28. Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018;77:98–103.

29. Shorey CL, Mulla RT, Mielke JG. The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: a systematic review. Brain Res 2023;1798:148157.

30. Munafò A, Burgaletto C, Di Benedetto G, et al. Repositioning of Immunomodulators: a ray of hope for Alzheimer’s disease? Front Neurosci 2020;14:614643.